The present invention relates to an oral solid non-pulsatile 24 hours prolonged-release composition comprising an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochloride, together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour； from 35% to 45% by weight of betahistine is dissolved in 2 hours； from 46% to 60% by weight of betahistine is dissolved in 4 hours； from 61% to 80% by weight of betahistine is dissolved in 8 hours； from 81% to 97% by weight of betahistine is dissolved in 16 hours； and from 98% to 100% by weight of betahistine is dissolved in 24 hours. It also relates to its use in therapy, particularly in the treatment of a vestibular disease or condition, more particularly in the treatment of Ménière's disease.
